• Table of Contents

    Jun 12, 2026, 11:03

  • What Is the Consensus Value of Patients’ Treatment-Risk Tolerance? Assessing a Stated-Preference Evidence Base for Inflammatory Bowel Disease

    Jun 1, 2026, 00:00

  • Understanding Societal Preferences for Priority by Disease Severity in England and Wales

    Jun 1, 2026, 00:00

  • Strengthening Methods and International Evidence on Health Inequality Aversion

    Jun 1, 2026, 00:00

  • Structural Barriers to Primary Care Access and Their Implications for Health-Related Quality of Life

    Jun 1, 2026, 00:00

  • Development and Pretesting of the Children and Young People’s Time-Use Questionnaire for Use in Economic Evaluation

    Jun 1, 2026, 00:00

  • Why Object to Inequalities in Health and Well-Being? A Mixed-Methods Exploration of Inequality Aversion With Members of the General Public

    Jun 1, 2026, 00:00

  • The Inequality-Adjusted Incremental Cost-Effectiveness Ratio

    Jun 1, 2026, 00:00

  • Assessing the Population-Health Loss From Funding High-Cost Medicines: Case Studies From Colombia and the Dominican Republic

    Jun 1, 2026, 00:00

  • An Overdue Denunciation of the Minimal Important Difference When Applied to Health State Values

    Jun 1, 2026, 00:00

  • Mapping Patient-Reported Outcomes Measurement Information System Pediatric-25 Profile to EQ-5D-Y-3L

    Jun 1, 2026, 00:00

  • A Systematic Review of Elicitation Methods for Distributional Preferences in Healthcare Regarding the Concentration and Dispersion of Health Benefits

    Jun 1, 2026, 00:00

  • Designing and Implementing Real-World Patient-Reported Outcomes—Emerging Recommendations: A Good Practices Report of an ISPOR Task Force

    Jun 1, 2026, 00:00

  • Beyond “Today”: Making Recall-Period Choices Clinically and Economically Meaningful

    Jun 1, 2026, 00:00

  • Advances in Methods and Measures for Equity-Informative Evaluations

    Jun 1, 2026, 00:00

  • Editorial Board

    Jun 1, 2026, 00:00

  • Integrating Generative Artificial Intelligence Into Evidence Synthesis: Opportunities, Safeguards, and Methodological Refinements

    Jun 1, 2026, 00:00

  • Validity, Reliability, and Framing Effects in Equity-Efficiency Trade-Off Studies: A Systematic Review

    Jun 1, 2026, 00:00

  • The Early Experiences of Health Technology Assessment Bodies in the Implementation of the European Union Health Technology Assessment Regulation for High-Risk Medical Devices: A Qualitative Study

    Jun 1, 2026, 00:00

  • Incorporating Equity and Financial Protection Criteria Into Essential Benefits Package Design: A Case Study of Infectious Diseases Interventions in Ethiopia

    Jun 1, 2026, 00:00

  • Conflicts of Interest in United States Food and Drug Administration Advisory Committees: A Systematic Literature Review

    Jun 1, 2026, 00:00

  • Dominance-Based Distributional Cost-Effectiveness Analysis of Cardiovascular Disease Risk Screening in Sri Lanka

    Jun 1, 2026, 00:00

  • Methodological Advances and Challenges in Indirect Treatment Comparisons: A Review of International Guidelines and Haute Autorité de Santé Transparency Committee Case Studies

    Jun 1, 2026, 00:00

  • Minimally Important Differences for Preference-Weighted Health Measurement Scales: There Is Nothing Mystical About Them

    Jun 1, 2026, 00:00

  • The Social Distribution of Quality-Adjusted Life Expectancy Among Social Deprivation Subgroups in China

    Jun 1, 2026, 00:00

  • Exploring Recall Periods for EQ-5D-5L and EQ-HWB-9: A Hong Kong Population Study

    Jun 1, 2026, 00:00

  • A Threshold Inequality Aversion Parameter Approach to Interpret Distributional Cost-Effectiveness Analysis Results

    Jun 1, 2026, 00:00

  • Value-Based Pricing of Health Services With Health Equity Considerations

    Jun 1, 2026, 00:00

  • Health Utilities and Disutilities Associated With Complications of Type 1 Diabetes: A Systematic Review and Recommendations for Health Economic Models

    Jun 1, 2026, 00:00

  • Editorial Board

    May 21, 2026, 11:08

  • Technological Maturity and Cost-Effectiveness of Medical Artificial Intelligence: A Systematic Review of Health Economic Evaluations

    May 1, 2026, 00:00

  • Switching From EQ-5D-3L to EQ-5D-5L in England: The Impact in NICE Technology Appraisals

    May 1, 2026, 00:00

  • Estimating the Global Macroeconomic Impact of Tuberculosis Among Children and Adolescents

    May 1, 2026, 00:00

  • A United Kingdom Value Set for the EQ-5D-5L

    May 1, 2026, 00:00

  • A Practical Method for Estimating Generalized Risk-Adjusted Cost-Effectiveness Utilities and Willingness-to-Pay Corrections

    May 1, 2026, 00:00

  • Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force

    May 1, 2026, 00:00

  • Development of a Brief Personal Health Agency Measure Among Patients Seeking Discretionary Musculoskeletal Specialty Care

    May 1, 2026, 00:00

  • Accounting for the Scarcity of Time as Patients Approach End of Life: The Construction of End-Weighted Time Toxicity

    May 1, 2026, 00:00

  • Influence of Initial Imaging Modality on Peri-Diagnostic Outcomes Among Pancreatic, Liver, Ovarian, and Bladder Cancers Without Routine Screening Programs: A Surveillance, Epidemiology, and End Results-Medicare Study

    May 1, 2026, 00:00

  • Estimating Heterogeneous Treatment Effects With Real-World Health Data: A Scoping Review of Machine Learning Methods

    May 1, 2026, 00:00

  • Valuing Child Health: An EQ-5D-Y-3L Value Set for the United States

    May 1, 2026, 00:00

  • Assessing the Role of Presurgical Information on Patient-Reported Outcomes: A Causal Analysis

    May 1, 2026, 00:00

  • Author Reply

    May 1, 2026, 00:00

  • Syringe Services Participants’ Preferences for Wound Care, HIV/Hepatitis C Virus Screening, and Opioid Use Disorder Treatment: A Discrete Choice Experiment

    May 1, 2026, 00:00

  • Optimizing Decision Making in Universal Newborn Hearing Screening: A Value of Information Perspective

    May 1, 2026, 00:00

  • No Differential Item Functioning of Patient-Reported Outcomes Measurement Information System Global Health Items by Neighborhood Socioeconomic Deprivation

    May 1, 2026, 00:00

  • Applying the Argument-Based Approach to Validation With Clinical Outcome Assessments: Strategies for Constructing a Rationale

    May 1, 2026, 00:00

  • Uncovering the Cost-Effectiveness of Theory-Based Implementation Approaches: A Health Economic Analysis of the Hide and Seek Project Trial

    May 1, 2026, 00:00

  • International Reference Pricing: Impact of Changing the Basket of Reference Countries on Ability to Reference and on Drug Launch Prices in 6 Markets

    May 1, 2026, 00:00

  • Table of Contents

    May 1, 2026, 00:00

  • From Prediction to Optimization: Machine Learning-Driven Integration of the Health Economic Value Chain and Revolution in System Efficiency

    May 1, 2026, 00:00

  • The Dark Side of the “Thousand-Faces” Vision: Ethical and Economic Reflections on Algorithmic Psychotherapy Matching

    May 1, 2026, 00:00

  • Preferences for Neurodevelopmental Screening Modalities for Children: A Labeled Discrete Choice Experiment Using Partial Choice Set Design

    May 1, 2026, 00:00

  • Welfare-Based Healthcare Planning: Methodology and Application to Thoracic Surgical Treatment of Lung Cancer in Germany

    May 1, 2026, 00:00

  • Editorial Board

    Apr 6, 2026, 13:15

  • Implications of Incorporating Environmental Sustainability Into Health Technology Assessment for Digital Health Technologies

    Apr 1, 2026, 00:00

  • Valuing Pediatric Technologies: A Framework for Parental Spillovers in Spinal Muscular Atrophy Bereavement

    Apr 1, 2026, 00:00

  • Impact of Heatwaves on Health-Related Quality of Life in Older Chinese Adults: A Longitudinal Cohort Study

    Apr 1, 2026, 00:00

  • Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis

    Apr 1, 2026, 00:00

  • Qini Curves for Potential Impact Assessment of Risk Predictive Models Informing Intervention Policies

    Apr 1, 2026, 00:00

  • Evaluation of Health Technology Assessment Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access

    Apr 1, 2026, 00:00

  • Table of Contents

    Apr 1, 2026, 00:00

  • Face Validation of an Artificial Intelligence Driven Tool for Clinical Triaging in Australian Public Oral Healthcare: A Pilot Study

    Apr 1, 2026, 00:00

  • Exploring Methods to Include Carbon Emissions Into a Health Technology Assessment: The Case of Remote Patient Monitoring

    Apr 1, 2026, 00:00

  • Toward a Harmonized Health Technology Assessment Framework for Digital Health Technologies in Europe

    Apr 1, 2026, 00:00

  • Deepening and Broadening: Revisiting Theories, Long-Term Economic Impact, and Diversity in Parental Bereavement After the Loss of a Child to Spinal Muscular Atrophy

    Apr 1, 2026, 00:00

  • From Consensus to Implementation: Advancing Patient-Centered Health Technology Assessment

    Apr 1, 2026, 00:00

  • Estimating the Shares of the Value of Branded Pharmaceuticals Accruing to Manufacturers and to Patients in the Thai Healthcare System

    Apr 1, 2026, 00:00

  • A Forward Agenda for Digital Health Technologies: Evidence That Works for Decisions

    Apr 1, 2026, 00:00

  • Author Reply

    Apr 1, 2026, 00:00

  • The Effect of Perspective, Duration, and Views on Death on the Valuation of Severe Health States

    Apr 1, 2026, 00:00

  • Reanalyzing Value Assessments in American Heart Association Clinical Practice Guidelines Using Health Years in Total Instead of Quality-Adjusted Life-Years

    Apr 1, 2026, 00:00

  • Author Reply

    Apr 1, 2026, 00:00

  • How Good Is Good Enough? A Simulation Study of Adaptive Health Technology Assessment

    Apr 1, 2026, 00:00

  • A Patient-Level Simulation Tool to Inform Data-Driven Pain Treatment Decisions and Policy in the US Military Health System

    Apr 1, 2026, 00:00

  • Cost Savings and Improved Clinical Outcomes From a Mobile Health Cardiovascular Disease Self-Management Program

    Apr 1, 2026, 00:00

  • Valuing Child and Adolescent Health States to Derive Utilities for Use in Economic Evaluation: A Good Practices Report of an ISPOR Task Force

    Apr 1, 2026, 00:00

  • A Systematic Review of the Methods and Quality of Economic Evaluations for Artificial-Intelligence-Assisted Cancer Screening or Diagnosis

    Apr 1, 2026, 00:00

  • Decision Analytic Models to Assess the Cost-Effectiveness of Prevention, Detection, and Treatment in Multiple Long-Term Conditions: A Scoping Review

    Apr 1, 2026, 00:00

  • System-Wide Use of Patient-Reported Outcome Measures in Organization for Economic Co-operation and Development Countries: Insights From a Health Policy Survey and Key Informant Workshops

    Apr 1, 2026, 00:00

  • Editorial Board

    Mar 11, 2026, 10:20

  • Impact of China’s National Drug Price Negotiation Policy on Availability, Affordability, and Regional Equity of Negotiated Drugs: A Multidimensional Nationwide Analysis, 2018 to 2021

    Mar 1, 2026, 00:00

  • Psychometric Performance of Skin, Self-Confidence, and Social Health-Related EQ-5D-5L Bolt-Ons in Patients With Atopic Dermatitis and Psoriasis in Germany

    Mar 1, 2026, 00:00

  • The Compounding Burden of Pregnancy Loss: A Longitudinal Analysis of Quality-of-Life Trajectories After Miscarriage

    Mar 1, 2026, 00:00

  • Priority for Self or Others? Incorporating Equity Considerations in a Preference-Based Health Value Assessment

    Mar 1, 2026, 00:00

  • Reversing Proxy Roles: Care Recipients as Proxies for Caregiver Health-Related Quality of Life

    Mar 1, 2026, 00:00

  • Economic Evaluation of Deprescribing in Older Adults: A Systematic Review

    Mar 1, 2026, 00:00

  • Table of Contents

    Mar 1, 2026, 00:00

  • Psychometric Properties of Cognition Bolt-Ons for the EQ-5D-3L and EQ-5D-5L: A Systematic Review

    Mar 1, 2026, 00:00

  • The Uneven Path of Psychological Distress: How Socioeconomic Status Shapes Distress Transitions in Australian Adults

    Mar 1, 2026, 00:00

  • Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care, and Well-Being Measures in the Context of Multiple Sclerosis

    Mar 1, 2026, 00:00

  • Quantifying Accuracy and Cost in Public Preferences for Artificial Intelligence in Radiation Therapy

    Mar 1, 2026, 00:00

  • Health Utility Decrements Associated With Social Isolation and Loneliness: Evidence From Australian Longitudinal Data

    Mar 1, 2026, 00:00

  • Return-on-Investment in Health Economic Evaluation: An Exploratory Analysis

    Mar 1, 2026, 00:00

  • Empirical Evidence and Conceptual Framework to Address the Indian Health Service Underfunding Challenge

    Mar 1, 2026, 00:00

  • Patient-Reported Outcome Measures in Clinical Trials: An Analysis of Trends From 2008 to 2023

    Mar 1, 2026, 00:00

  • Author Reply

    Mar 1, 2026, 00:00

  • Genomic Testing in Australia: A Budget Impact Analysis Using Diffusion Modeling From a Healthcare System Perspective

    Mar 1, 2026, 00:00

  • Comparative Effectiveness of Ixekizumab Versus Ustekinumab in Patients With Psoriasis: A Randomized Controlled Trial Replication Using Data From an Observational Study (Shanghai Psoriasis Effectiveness Evaluation Cohort)

    Mar 1, 2026, 00:00

  • Disinvestment and Health Spending Efficiency in Latin America and the Caribbean: A Case Study of Colombia

    Mar 1, 2026, 00:00

  • Estimating the Willingness-to-Pay per Quality-Adjusted Life-Year to Aid Health Technology Assessment in India

    Mar 1, 2026, 00:00

  • Evaluating Long-Term Health Disparity Impacts of Clinical Algorithms Using a Patient-Level Simulation Framework

    Mar 1, 2026, 00:00

  • Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular Atrophy

    Feb 1, 2026, 00:00

  • Preferences for Adopting Artificial Intelligence in Radiation Therapy Treatment: A Discrete Choice Experiment

    Feb 1, 2026, 00:00

  • Should Early-Stage NIH Funding Influence Pharmaceutical Drug Pricing?

    Feb 1, 2026, 00:00

  • Hospital and Regional-Level Factors Associated With Negotiated Payer Rates for Hip Fracture Fixation: A Multistate Analysis

    Feb 1, 2026, 00:00

  • Means Can Be Deceiving: Comparing and Contrasting Risk Tolerance Estimates From a Discrete-Choice Experiment and a Threshold Technique Exercise

    Feb 1, 2026, 00:00

  • What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective

    Feb 1, 2026, 00:00

  • Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Special Interest Group Report

    Feb 1, 2026, 00:00

  • The Cost-Effectiveness of Community Health Workers in Primary Health Care: A Systematic Review

    Feb 1, 2026, 00:00

  • A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making

    Feb 1, 2026, 00:00

  • Mapping Methodologies for Economic Evaluation of Digital Health Technologies: A Scoping Review

    Feb 1, 2026, 00:00

  • PROM-ising Progress? Trends in Patient- and Clinician-Reported Outcome Measures in US Food and Drug Administration Orphan Drug Labels

    Feb 1, 2026, 00:00

  • Cost-Effectiveness of Reorganizing the Approach to Diabetes Through the Application of Registries: An Innovative Model to Organize Diabetes Care in First Nations Communities in Canada

    Feb 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children With Asthma

    Feb 1, 2026, 00:00

  • Comparing Psychometric Properties of 6 of the 5-Level and 3-Level EQ-5D Bolt-Ons in a Large, Multinational, Longitudinal General Population Sample

    Feb 1, 2026, 00:00

  • Development of a Preference Weighting System for the Parent-Proxy Child Chronic Cough Quality-of-Life Instrument

    Feb 1, 2026, 00:00

  • Long-Term Outcomes and Cost-Effectiveness of Artificial Intelligence for Breast Cancer Screening: A Modeling Study

    Feb 1, 2026, 00:00

  • EQ-5D-5L in Multiple Sclerosis: Estimated Utility Values, Minimal (Clinically) Important Changes, and Direct and Indirect Influences Over Time

    Feb 1, 2026, 00:00

  • Derivation of Meaningful Change Thresholds for European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 in Patients With Small-Cell Lung Cancer

    Feb 1, 2026, 00:00

  • How Do Different Health States Impact Preferences for Social-Care-Related Quality of Life: An Exploration of EQ-5D-5L and Adult Social Care Outcomes Toolkit Using a Vignette Approach

    Feb 1, 2026, 00:00

  • Editorial Board

    Jan 23, 2026, 08:45

  • Table of Contents

    Jan 23, 2026, 08:41

  • Table of Contents

    Jan 5, 2026, 12:03

  • Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries

    Jan 1, 2026, 00:00

  • Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds

    Jan 1, 2026, 00:00

  • A Generalized Risk-Adjusted Cost-Effectiveness Economic Model for Measuring the Value of Interventions That Delay Mobility Impairment Across Neurological Conditions

    Jan 1, 2026, 00:00

  • Unlocking Patient Preferences: The Potential of Stated-Preference Methods in Clinical Decision Making

    Jan 1, 2026, 00:00

  • Incorporating Informal Caregiving Time Into Cost-Effectiveness Analysis for Adults Aged 50 and Older: Estimating From Health-Related Quality of Life and Functional Status

    Jan 1, 2026, 00:00

  • Comparing Adolescent and Adult Preferences for EQ-5D-Y-3L Health States in Hong Kong

    Jan 1, 2026, 00:00

  • Integrating Price Benchmarks and Comparative Clinical Effectiveness to Predict Initial Price Offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027)

    Jan 1, 2026, 00:00

  • Health Inequality Aversion in the United States

    Jan 1, 2026, 00:00

  • Clinical Outcomes and Measures for Vaginal Relaxation Syndrome: A Systematic Review

    Jan 1, 2026, 00:00

  • The Cost-Effectiveness of Collagenase Injection Versus Limited Fasciectomy for Moderate Dupuytren’s Contracture: An Economic Evaluation of the Dupuytren’s Interventions Surgery Versus Collagenase Trial and a Decision Analytical Model

    Jan 1, 2026, 00:00

  • Toward a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report

    Jan 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children Aged 8 to 18 Years With Eczema

    Jan 1, 2026, 00:00

  • Editorial Board

    Jan 1, 2026, 00:00

  • Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions

    Jan 1, 2026, 00:00

  • Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program

    Jan 1, 2026, 00:00

  • Operationalizing Distributional Cost-Effectiveness in Genomic Medicine: A United States–Focused Comment

    Jan 1, 2026, 00:00

  • Implications of Value Set Choice on EQ-5D-Y-3L Child and Proxy Health-Related Quality of Life Ratings: What to Do When a Country-Specific “Y” Value Set Is Unavailable?

    Jan 1, 2026, 00:00

  • Methodological Insights From Health Valuation Studies in Low- and Middle-Income Countries: A Scoping Review

    Jan 1, 2026, 00:00

  • Predicting Healthcare Utilization Outcomes With Artificial Intelligence: A Large Scoping Review

    Jan 1, 2026, 00:00

  • Adult Social Care Outcomes Toolkit and ICEpop Capability Measure in Decision Making: A Review of NICE Social Care and Public Health Guidelines

    Jan 1, 2026, 00:00

  • Disclaimer

    Dec 19, 2025, 11:50

  • Editorial Board

    Dec 16, 2025, 09:49

  • EPH239 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Squamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • EE737 Treatment Patterns of Rare Immunodeficiencies With Special Regard to Antibiotics: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • EPH4 A Person-Centered Approach: Exploring Social Support Network and Mental Health Among Shoebox House Residents in Hong Kong

    Dec 1, 2025, 00:00

  • EE328 Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework

    Dec 1, 2025, 00:00

  • EE501 Healthcare Costs of Mammography Screening and Breast Cancer Treatment: A Registry-Based Study From Norway

    Dec 1, 2025, 00:00

  • PCR84 Evaluating the Role of Patient-Reported Outcomes in Phase 4 Clinical Trials: Trends, Applications, and Implications for Postmarketing Surveillance

    Dec 1, 2025, 00:00

  • HPR147 Navigating the MFN Pricing Era: Strategic Imperatives for Biopharma

    Dec 1, 2025, 00:00

  • EE676 Surviving but Not Earning? Long-term Income Trajectories in Working-Age mIDH Glioma Patients: Stratification by Radiotherapy/Chemotherapy Exposure

    Dec 1, 2025, 00:00

  • HSD122 Utilization of Informal WhatsApp for Pre- and Postnatal Referral Services in the Kwadaso Municipality of Ghana

    Dec 1, 2025, 00:00

  • MSR2 A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa

    Dec 1, 2025, 00:00

  • HTA53 Beyond Productivity: How Professional Identity Shapes Generative AI Adoption Among Medical Writing Professionals

    Dec 1, 2025, 00:00

  • HTA361 What Did Time Reveal Evaluating the Accuracy of Parametric Model Predictions Against Long-Term Observed Data for Larotrectinib?

    Dec 1, 2025, 00:00

  • EE528 Impact of Comparator Type on Cost-Effectiveness Outcomes: Insights From ASMR III Evaluations in France

    Dec 1, 2025, 00:00

  • CO16 Assessing the Real-World Impact of Earlier Initiation of Anti-Tumor Necrosis Factor vs. Conventional Synthetic DMARDs on Clinical and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis in Europe

    Dec 1, 2025, 00:00

  • EE359 Economic Burden of COVID-19-Related Hospitalizations in Finland: A 4-year Longitudinal Analysis

    Dec 1, 2025, 00:00

  • RWD68 Economic and Clinical Burden of MACE-Related Rehospitalizations in Patients With Obesity: A Real-World Study Based on Italian Healthcare Data

    Dec 1, 2025, 00:00

  • MSR167 Piloting a GenAI Agent for Structured Quality Appraisal of Network Meta-Analyses Using the ISPOR-AMCP-NPC Checklist

    Dec 1, 2025, 00:00

  • HPR5 A Comparative Analysis of Similarities and Differences of RWE Standards Across Regulatory and Health Technology Assessment Bodies

    Dec 1, 2025, 00:00

  • PCR136 Improving the Conceptual Coverage of the 15-item Penn Parkinson’s Daily Activity Questionnaire (PDAQ-15) for Use in the Mild-to-Moderate Lewy Body Dementia Population

    Dec 1, 2025, 00:00

  • HTA170 Have Delays in Vaccine Market Access Improved in Europe and the US Over the Last Decade?

    Dec 1, 2025, 00:00

  • HPR205 The Implementation of the European Charter of Patients’ Rights in Hungarian and Romanian Healthcare Legislation With Special Emphasis on Informed Consent

    Dec 1, 2025, 00:00

  • EE133 Clinical Management and Outcomes of Patients in England With eGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Observational Study and Its Impact on UK Health Technology Assessments

    Dec 1, 2025, 00:00

  • EE644 Reducing the Transmission and Annual Burden of Influenza in the UK With Baloxavir Marboxil: A Cost-Effectiveness Analysis Using Evidence From the CENTERSTONE Trial

    Dec 1, 2025, 00:00

  • HTA137 Evidence of Mapping Malpractice? A Review of Mapping Algorithm Usage in NICE Health Technology Appraisals

    Dec 1, 2025, 00:00

  • HPR82 Evolution of Negotiations and Contracts for Reimbursement of Pharmaceuticals in Greece Between 2020 and 2025: Onwards and Upwards

    Dec 1, 2025, 00:00

  • HTA339 Transparency Tested: Conflict of Interest in EU HTA

    Dec 1, 2025, 00:00

  • SA30 Designing Digital Healthcare Professional Surveys: A Methodological Overview

    Dec 1, 2025, 00:00

  • EE308 Cost-Utility Analysis of Standard-Dose vs. High-Dose Influenza Vaccination in Adults Aged ≥ 65 Years in Italy

    Dec 1, 2025, 00:00

  • P20 The Frequency of Mentions and Impact of Patient Input in HTA Decision Making in Cell and Gene Therapies Across the UK, Canada, and Australia

    Dec 1, 2025, 00:00

  • EE66 Assessing Treatment Efficiency Indicated in Rare Diseases: Learning From the CEESP Has Economic Opinions

    Dec 1, 2025, 00:00

  • RWD133 Parental Vaccine Hesitancy in Children With Comorbidities: A Comparative Analysis

    Dec 1, 2025, 00:00

  • EE143 Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain

    Dec 1, 2025, 00:00

  • PCR187 Population-Level Impact of Emicizumab in Algeria: A 25-Year Projection

    Dec 1, 2025, 00:00

  • HSD93 Real-World Differences in Breast Cancer Management by Detection Method: A Czech National Analysis

    Dec 1, 2025, 00:00

  • HPR168 Quo Vadis? The Emerging Role of the Medicines and Healthcare Products Regulatory Agency (MHRA) in an Evolving Regulatory Landscape

    Dec 1, 2025, 00:00

  • SA28 Decoding Diagnosis Delay in Juvenile Idiopathic Arthritis (JIA)

    Dec 1, 2025, 00:00

  • HTA146 Exploring Nordic Real-World Evidence Sources for a PICO Assessment of a Hypothetical Oncology Drug and Medical Device Product

    Dec 1, 2025, 00:00

  • EE673 Strategies for More Cost-Effective HrHPV Screening: A Simulation Study of Pooled Testing Based on Real-World Data in Low- and Middle-Income Countries

    Dec 1, 2025, 00:00

  • CO236 The Clinical Burden and Complications Associated With Glycogen Storage Disease Type Ia (GSDIa): Results From a Systematic Literature Review

    Dec 1, 2025, 00:00

  • EPH130 Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends

    Dec 1, 2025, 00:00

  • EPH34 Burden of Hospitalized Viral Respiratory Infections in Fran Insights From the 2022-2023 Season

    Dec 1, 2025, 00:00

  • HTA3 A Comparison of the NICE HST Program With Health Technology Assessments of Ultra-Orphan Drugs From France and Germany

    Dec 1, 2025, 00:00

  • HTA323 The Landscape of the Use of Artificial Intelligence and Machine Learning (AIMI) Methods in Health Technology Assessment (HTA) Submissions

    Dec 1, 2025, 00:00

  • MSR161 Overfitting Mitigation in Neural Networks: Could Ergodic Regularization Be the Future of AI?

    Dec 1, 2025, 00:00

  • EE125 Climate Impact of CAR-T Cell Therapy in the Netherlands: A Comparison on the Use Phase Emission Between Standard of Care and CAR-T Cell Therapy in Hemato-oncology

    Dec 1, 2025, 00:00

  • HTA185 HTA for Obesity and T2DM Indications: A Review and Recommendations for Future Appraisals

    Dec 1, 2025, 00:00

  • HPR4 A Comparative Analysis of Regulatory Divergence in Expedited Oncology Approvals: Evidence, Pathways, and Timelines Across FDA, EMA, TGA, and PMDA

    Dec 1, 2025, 00:00

  • RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care

    Dec 1, 2025, 00:00

  • CO195 Qualitative Exit Interviews in Charcot-Marie-Tooth Type-2 Sorbitol Dehydrogenase (CMT-SORD) Deficiency

    Dec 1, 2025, 00:00

  • MSR228 Eliciting Health State Preferences With Analytical Hierarchy Process: An Illustration With EQ-5D-5L

    Dec 1, 2025, 00:00

  • CO75 Disease Progression Modeling for an Ultra-Rare Disease: Lysosomal Acid Lipase Deficiency (LAL-D)

    Dec 1, 2025, 00:00

  • P4 Simulating Sponsor-HTA Conversations: A Multi-Agent GenAI Framework for Reimbursement Processes

    Dec 1, 2025, 00:00

  • EPH142 Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia Among United States Medicare Beneficiaries

    Dec 1, 2025, 00:00

  • EE172 Cost-Effectiveness of Sulopenem vs. Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Decision Analysis

    Dec 1, 2025, 00:00

  • HTA313 The Acceptability of Wearables in Remote Monitoring According to Health Technology Assessment HTA Bodies

    Dec 1, 2025, 00:00

  • HSD43 Environmental Impact of Intravenous vs. Oral Chemotherapy in Fran A 1000-Patient Model-Based Assessment

    Dec 1, 2025, 00:00

  • EE483 Has the IRA Impacted International Price Differentials? Comparing US and German Drug Prices in the Era of MFP

    Dec 1, 2025, 00:00

  • HTA190 HTA Submission Trends for EMA-Approved Oncology NASs Prior to the EU HTA Regulation 2018-2023

    Dec 1, 2025, 00:00

  • PCR176 Patient Perspectives on Unmet Needs in mCRPC: Emphasizing Improved Quality of Life and Delay in Chemotherapy

    Dec 1, 2025, 00:00

  • HTA362 What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques

    Dec 1, 2025, 00:00

  • HTA162 German HTA Outcomes for Rare Disease Drugs When Orphan Designation Does Not Legally Determine Added Benefit

    Dec 1, 2025, 00:00

  • HPR150 Optimizing Pricing Models for Weight-Based and Multistock-Keeping Unit (SKU) Therapies in the EU4

    Dec 1, 2025, 00:00

  • RWD37 Comorbidities As a Risk Predictor of Kidney Disease Progression Among Patients Diagnosed With Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • EE718 The Ongoing Challenge of Clostridioides Difficile Infection in Austria: Economic Evaluation of Two Recommended Treatment Pathways

    Dec 1, 2025, 00:00

  • RWD98 Hospital Burden of Pulmonary Arterial Hypertension in Fran A Real-World Study Using the French Hospitalization Database (PMSI)

    Dec 1, 2025, 00:00

  • EE496 Healthcare and Economic Burden of Intravenous and Subcutaneous Immunoglobulin Treatment in Three Autoimmune Neuromuscular Diseases: A Bicentric Spanish Experience

    Dec 1, 2025, 00:00

  • RWD179 The Burden and Management of Flares Among Pregnant Patients With Generalized Pustular Psoriasis (GPP): Real-World Evidence (RWE) From the Global SCRIPTOR Study

    Dec 1, 2025, 00:00

  • EE464 Fecal Microbiota Transplantation for Irritable Bowel Syndrome With Constipation: A Decision-Analytical Analysis

    Dec 1, 2025, 00:00

  • PCR45 Cognitive Debrief of the PROMIS Parent Proxy Mobility Item Bank in Caregivers of Children Living With Duchenne Muscular Dystrophy

    Dec 1, 2025, 00:00

  • HTA151 From French Early Access to Regular Reimbursement: How Do Prices Shift Post-HTA?

    Dec 1, 2025, 00:00

  • EE212 Cost-Effectiveness Analysis of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for Patients With High-Risk Early Stage Triple-Negative Breast Cancer in Chile

    Dec 1, 2025, 00:00

  • CO98 Epidemiological Study of Pulmonary Hypertension in Patients With Interstitial Lung Diseases (PH-ILD) in Gree A Retrospective Multicenter Study

    Dec 1, 2025, 00:00

  • CO258 US Population-Level Clinical Impact of Lorlatinib Treatment on ALK+ Metastatic Non-Small Cell Lung Cancer Outcomes

    Dec 1, 2025, 00:00

  • HTA73 Challenges in the German AMNOG Procedure: The Need for National PICO Transparency and Optimized Consultation Windows in the Context of EU-HTA

    Dec 1, 2025, 00:00

  • EPH79 Epidemiology and Institutional Treatment Distribution of Patients With Myelofibrosis (MF) in Germany: Insights From a Real-World Evidence Study

    Dec 1, 2025, 00:00

  • EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • RWD108 Integrating Agentic AI With LLM Workflows for Cohort Comparison in Healthcare Analytics

    Dec 1, 2025, 00:00

  • HTA183 HTA and Regulatory Perspectives on Robustness of Evidence and Management of Uncertainties

    Dec 1, 2025, 00:00

  • EE489 Health Economic Assessment of Cefepime-Enmetazobactam for Treating Complicated Urinary Tract Infections: A German Payer Perspective

    Dec 1, 2025, 00:00

  • HPR125 Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024

    Dec 1, 2025, 00:00

  • MT18 From Development to Reimbursement Evidence-Generation Strategies for HealthTech in Europe

    Dec 1, 2025, 00:00

  • EPH205 Real-World Treatment Patterns of Trofinetide in Rett Syndrome: Analysis of Medical Pharmacy-Linked Claims Database in the United States

    Dec 1, 2025, 00:00

  • RWD123 Medication Use in Indolent Systemic Mastocytosis (ISM) in Germany Prior to Avapritinib EMA Approval

    Dec 1, 2025, 00:00

  • EE526 Impact of Budesonide-Glycopyrronium Formoterol Initiation on Healthcare Resource Utilization and Carbon Emissions in Patients With COPD in Spain: Insights From the ORESTES Study

    Dec 1, 2025, 00:00

  • EE415 Establishing Robust and Adaptive Willingness-to-Pay Thresholds for Taiwan's National Health Insuran A Case Study of Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • RWD18 Archival Sample Testing for Real-World Insights: Innovative Approaches to Enriching Retrospective Studies With Biomarker Data

    Dec 1, 2025, 00:00

  • P54 Thus SPOKE the TA: Querying NICE Technology Assessments Using Generative AI and RAG

    Dec 1, 2025, 00:00

  • RWD24 Association of Recurrences With Healthcare Resource Utilization in High-Risk Non-Muscle Invasive Bladder Cancer Patients Across Europe: A Real-World Survey

    Dec 1, 2025, 00:00

  • MSR75 AI Time and Motion - Analysis of the Accuracy and Efficiency of AI for HTA-Standard SLRs

    Dec 1, 2025, 00:00

  • EE418 Estimating Costs Avoided by Preventing Recurrences With a BRCA Testing Strategy in High-Risk HER2-Negative Adjuvant Breast Cancer Patients in Spain

    Dec 1, 2025, 00:00

  • EPH9 A Systematic Literature Review to Identify Potential Risk Factors and Causative Organisms for Neonatal Sepsis in Indian Neonates

    Dec 1, 2025, 00:00

  • EE221 Cost-Effectiveness Analysis of the Prostate Health Index (PHI) Test After a Prostate-Specific Antigen (PSA) Test in UK

    Dec 1, 2025, 00:00

  • HPR93 Fair Pricing of Innovative Medicines From Definition to Application in CAR-T Cell Therapy

    Dec 1, 2025, 00:00

  • HSD35 Disability Resource Utilization and Caregiver Support Among a Real-World Sample of Patients With Transthyretin Amyloidosis With Polyneuropathy

    Dec 1, 2025, 00:00

  • EPH240 The Health Impact of Pembrolizumab Plus Chemotherapy in the First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC) in Türkiye

    Dec 1, 2025, 00:00

  • HPR170 Real-World Data for External Controls: Insights From EMA Regulatory Submissions

    Dec 1, 2025, 00:00

  • SA2 A Patient-Level Simulation to Bridge Data Gaps in Cost-Effectiveness Modeling of B-VEC for Dystrophic Epidermolysis Bullosa

    Dec 1, 2025, 00:00

  • HPR157 Paying for Advanced Therapy Medicinal Products: Are Spreading Payments Over Time the Solution?

    Dec 1, 2025, 00:00

  • EPH113 Fostamatinib-Induced Hepatomegaly: A Novel Signal Identified Through US Food and Drug Administration Adverse Event Reporting System (FAERS) Database

    Dec 1, 2025, 00:00

  • CO194 Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Illness Among High-Risk Adults Aged 18-59 Years in Germany

    Dec 1, 2025, 00:00

  • EPH230 The Changing Prevalence of Multicomorbid Patients in the US

    Dec 1, 2025, 00:00

  • P26 Approximating Competing Risk Events From Published Kaplan-Meier Curves Using Simultaneity-Based Event Assignment Methods

    Dec 1, 2025, 00:00

  • PT2 Frequency and Impact of External Comparator Arms in Oncology HTA Assessments With Single-Arm Trials in the UK, France, and Germany From 2014 to 2024

    Dec 1, 2025, 00:00

  • RWD156 Real-World Evidence Study on Healthcare Resource Utilization (HCRU) Among Cancer Patients in the Helsinki and Uusimaa (HUS) Region, Finland

    Dec 1, 2025, 00:00

  • EE547 Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions

    Dec 1, 2025, 00:00

  • HTA168 Harmonization or Hindrance? A Strategic Analysis of Divergent National Requirements Under the EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • HSD112 Transforming Pediatric Type 1 Diabetes Care in Bulgaria Through Structured Patient Journey Analysis

    Dec 1, 2025, 00:00

  • EE491 Health Economic Evaluation Model for Pancreatic Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • EE24 A Nonactive Implant for the Treatment of Chronic Gastro-esophageal Reflux Disease: A Cost-Effectiveness Evaluation From the Perspective of German Healthcare

    Dec 1, 2025, 00:00

  • RWD152 Real-World Evidence From Community Oncology: Assessing Secular Trends in Ovarian Cancer Diagnoses From 2014 to 2024

    Dec 1, 2025, 00:00

  • MSR180 Reevaluating Cost-Effectiveness: A Holistic Framework for Assessing Disease-Modifying Treatments in Type 1 Diabetes

    Dec 1, 2025, 00:00

  • HTA139 Evolution of Acceptance of Evidence and PMA Outcomes by HTA Authorities for ATMPs in the EU4 and the UK 2017-2025

    Dec 1, 2025, 00:00

  • PCR253 Understanding Patient Priorities in Psoriasis Treatment: A Review of Key Decision-Making Drivers

    Dec 1, 2025, 00:00

  • HTA64 Canadian HTA Decisions (2020-2023): Comparing CDA-AMC and INESSS Recommendations on Drug Reimbursement

    Dec 1, 2025, 00:00

  • EE363 Economic Burden Of Primary Biliary Cholangitis (PBC) in Spain

    Dec 1, 2025, 00:00

  • EE560 Introducing the Parameter Outcome Overview Plot: A New Addition to the Sensitivity Analysis Armory for Economic Models

    Dec 1, 2025, 00:00

  • EPH98 Examination of Attitudes Towards Vaccinations Among the Hungarian Population

    Dec 1, 2025, 00:00

  • PCR101 Gaps in Evidence on Burden and HRQoL in Small-Cell Lung Cancer: Findings From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • HPR187 Socioeconomic Disparities in Postpartum Depression Following Abortion Restrictions: A Difference-in-Differences Analysis of Medicaid Data Post-Dobbs

    Dec 1, 2025, 00:00

  • CO111 Evaluating Therapeutic Landscape in Radio-Iodine-Refractory–Differentiated Thyroid Cancer (DTC): A Bayesian Network Meta-Analysis of Clinical Efficacy

    Dec 1, 2025, 00:00

  • PCR43 Characterizing and Quantifying Impacts of Neuromyelitis Optica Spectrum Disorder (NMOSD) on Patients and Caregivers

    Dec 1, 2025, 00:00

  • CO85 Effectiveness of Inclisiran and Evolocumab in LDL-C Goal Attainment: A Hybrid Decision Tree-Markov Model Analysis

    Dec 1, 2025, 00:00

  • EPH236 The Health Impact of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab Treatment for High-Risk Early Stage Triple-Negative Breast Cancer (eTNBC) in Türkiye

    Dec 1, 2025, 00:00

  • EPH211 Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy Patients in the Brazilian Public Health System: A Real-World Study

    Dec 1, 2025, 00:00

  • EE447 Evaluating the Societal and Economic Impact of Immunotherapy for Melanoma Treatment in Bulgaria

    Dec 1, 2025, 00:00

  • EPH189 Prevalence of Meningococcal Carriage by Serogroup in Adolescents and Young Adults: A Global Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • CO36 Cardioprotective Medication Use Among Diabetic Patients With ASCVD in Qatar's Primary Care Setting

    Dec 1, 2025, 00:00

  • HTA86 Comprehensive Clinical Evaluation of Amphotericin B in the Treatment of Invasive Fungal Disease in China

    Dec 1, 2025, 00:00

  • EPH87 Estimating the Eligible Population for Anti-Amyloid Therapy in Finland

    Dec 1, 2025, 00:00

  • RWD185 Trends and Disparities in Prostate Cancer Incidence Prevalence and Survival: A SEER Analysis 2000-2022

    Dec 1, 2025, 00:00

  • EE229 Cost-Effectiveness Evaluation of Combined Cervical Cancer Screening With CINtec PLUS in the Czech Republic

    Dec 1, 2025, 00:00

  • MSR217 Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-Term Treatment Effect: An Example in Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • MSR212 Use of a Nonparametric Bayesian Method to Model Health State Preferences: An Application to UAE EQ-5D-5L Valuations

    Dec 1, 2025, 00:00

  • EE633 Real-World Cost of Automated Red Blood Cell Exchange for Sickle Cell Disease in Kenya: A Cost-Reimbursement Gap Analysis From a Public Sector Perspective

    Dec 1, 2025, 00:00

  • EE195 Cost-Effectiveness Analysis of CYP2C19 Genotype-Guided Antiplatelet Therapy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in the Netherlands

    Dec 1, 2025, 00:00

  • EPH172 Objective Real-World Caregiver Costs and Lost Time for Absences and Family Medical Leaves in the United States for Employees Whose Spouses Have Dementia and/or Alzheimer’s Disease and Patient Direct Costs

    Dec 1, 2025, 00:00

  • EPH215 Site-Specific Wastewater-Based Surveillance in Early Detection of COVID-19 New Cases and Prediction of Mass Testing Outcomes in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • EE166 Cost Effectiveness and Budget Impact Analysis of Benralizumab for Treating Severe Uncontrolled Eosinophilic Asthma in Egypt

    Dec 1, 2025, 00:00

  • CO9 An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal-Bolus Insulin

    Dec 1, 2025, 00:00

  • CO12 APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes

    Dec 1, 2025, 00:00

  • HPR24 Analysis of Historical European Medicines Agency (EMA) Marketing Authorization (MA) Timelines: Will EU Joint Clinical Assessment (JCA) Timelines Be Longer Than Expected?

    Dec 1, 2025, 00:00

  • EPH82 Epidemiology of Diabetes Mellitus in Pregnancy in Hungary: Trends and Future Projections

    Dec 1, 2025, 00:00

  • EE112 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in France

    Dec 1, 2025, 00:00

  • EE79 Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States (US)

    Dec 1, 2025, 00:00

  • EPH31 Budget Impact of an Organized Diabetes Screening in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • CO183 Potential Benefits of Universal Influenza Vaccination on Health Outcomes and Costs in Mexico

    Dec 1, 2025, 00:00

  • EE18 A Health Economic Evaluation Framework for Implementing a Digital Survivorship Passport for Childhood Cancer Survivors

    Dec 1, 2025, 00:00

  • MT16 Evaluating Digital Health Tools in the UK for Type 1/2 Diabetes: An Overview of the Evidence Critiques

    Dec 1, 2025, 00:00

  • EE552 Indirect Treatment Comparisons in Economic Evaluations Submitted to the French Health Authority (CEESP) Since 2014

    Dec 1, 2025, 00:00

  • EE106 Budget Impact of Implementing a Case-Finding Program in UK Patients at High Risk for COPD to Explore Cost Savings Due to Earlier Diagnosis

    Dec 1, 2025, 00:00

  • MSR207 Turning the Tables: AI Halves Table Extraction Time in HEOR Systematic Reviews

    Dec 1, 2025, 00:00

  • MT5 Artificial Intelligence in Health Economics: Opportunities and Challenges for the Future: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • PCR110 Health Utility Values in Adults With Primary Biliary Cholangitis: A Global Systematic Literature Review

    Dec 1, 2025, 00:00

  • Inequality Aversion in Health: Eliciting Aversion to Univariate Health Inequalities Across Different Health Distributions

    Dec 1, 2025, 00:00

  • EPH2 A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population

    Dec 1, 2025, 00:00

  • HPR194 The Clawbacks Paradox: When Abusing a Simple Approach Has the Most Complicated and Problematic Consequences for Patients and Healthcare Systems

    Dec 1, 2025, 00:00

  • EE272 Cost-Effectiveness of rhTNK-tPA vs. rt-PA for Acute Ischemic Stroke Patients Within 4.5H of Symptom Onset in China

    Dec 1, 2025, 00:00

  • EPH99 Examining Knowledge Regarding Needlestick Injuries Among Students in Higher Healthcare Education

    Dec 1, 2025, 00:00

  • EE304 Cost-Utility Analysis of Linzagolix 200 mg Plus Add-back Therapy (Linzagolix+ABT) for Symptomatic Treatment of Endometriosis

    Dec 1, 2025, 00:00

  • CO102 Estimating the Mean Time in Treatment-Free Remission for Patients in Early Line CML

    Dec 1, 2025, 00:00

  • SA90 Systematic Review of Doubly Robust Methods for Population-Adjusted Indirect Comparisons

    Dec 1, 2025, 00:00

  • EE438 Evaluating the Cost-Effectiveness of Nasal Adrenaline Spray vs. Adrenaline Autoinjector for Treatment of Anaphylaxis: A Cost-Utility Modeling Approach

    Dec 1, 2025, 00:00

  • RWD155 Real-World Evidence of Atezolizumab in Unresectable Recurrent NSCLC: Insights From Japan's Next-Generation Medical Infrastructure Act

    Dec 1, 2025, 00:00

  • HPR14 Access and Evolving Eviden A European HTA Analysis of Innovative Medicines Under Evidence Generation Agreements

    Dec 1, 2025, 00:00

  • EPH250 The Longevity Conundrum: Population Aging in the UK

    Dec 1, 2025, 00:00

  • P22 Validation of Primary Care Resource Use and Costs in OMOP-Mapped vs. Source CPRD Aurum Data

    Dec 1, 2025, 00:00

  • P6 Potential Modifiers of Cost-Effectiveness Thresholds: Public Perspectives on Prioritization in Healthcare Spending

    Dec 1, 2025, 00:00

  • EE348 Early Stage Health Economic Evaluation of IMMUTOL Gene Therapy for Relapsing/Remitting Multiple Sclerosis in the Netherlands

    Dec 1, 2025, 00:00

  • MSR186 Simulated Treatment Comparisons Using Jackknife Pseudo Values for Population-Adjusted Marginal Effect Estimation

    Dec 1, 2025, 00:00

  • P12 Work Productivity Loss in Individuals Due to Respiratory Infections: A Questionnaire Survey of Employees in Denmark

    Dec 1, 2025, 00:00

  • CO175 Overall Treatment Landscape of Mucosal Melanoma

    Dec 1, 2025, 00:00

  • HTA130 Evaluating Clinical Similarity: A Systematic Review of Methods Used Within National Institute for Health and Care Excellence (NICE) Cost-Comparison Evaluations (CCEs) When Relying on Statistically Nonsignificant Differences From Indi ...

    Dec 1, 2025, 00:00

  • MSR83 Eliciting Patients' and Clinicians' Preferences on Adjuvant Treatment for HR+/HER2- Early Breast Cancer: Design of a Probabilistic Threshold Technique in Italy

    Dec 1, 2025, 00:00

  • HTA147 Focus on Two Years of Economic Opinions on Solid Cancers (2023-2024): What Are the Specific Features vs. 2021-2022?

    Dec 1, 2025, 00:00

  • HPR235 Utilization of Glucagon-Like Peptide-1 Receptor Agonists in the Irish Healthcare System

    Dec 1, 2025, 00:00

  • HPR197 The Disease Burden of Respiratory Syncytial Virus Among the Adult Population in Greece

    Dec 1, 2025, 00:00

  • MSR58 Comparing Individualized Treatment Effect Inference Methods Through a Simulation Study

    Dec 1, 2025, 00:00

  • EE728 The VIS1ON Horizon Scanning Model: Predicting the Evolution of Direct NHS Expenditure for Type 1 Diabetes in Italy up to 2028

    Dec 1, 2025, 00:00

  • PCR139 Informing Health System Reform Through Patient Perspectives: Saudi Arabia’s OECD Paris Survey Results

    Dec 1, 2025, 00:00

  • EE54 Application and Future Potential of Generative Artificial Intelligence (Gen AI) And Large Language Model (LLM) In Health Economics and Outcomes Research (HEOR)

    Dec 1, 2025, 00:00

  • HTA105 Determinants of Willingness to Pay Thresholds in NICE Oncology Technology Appraisals

    Dec 1, 2025, 00:00

  • MSR87 Estimand Framework in the Setting of Observational Studies: Current Landscape and Future Directions

    Dec 1, 2025, 00:00

  • EE77 Bridging the Gap: Why Cost-Effectiveness Analyses of Congenital Heart Interventions Are Critical for Person-Centered Value-Based Care

    Dec 1, 2025, 00:00

  • PT13 Mapping the Measurement Gap: Patient-Reported Outcomes Across the Obesity Care Continuum in the GLP-1 Era

    Dec 1, 2025, 00:00

  • HPR75 Evaluating the Costs and Benefits of Innovative Pricing and Payment Models in Europe

    Dec 1, 2025, 00:00

  • EE283 Cost-Minimization Analysis of Aripiprazole 2-Month Ready-to-Use vs. Other Long-Acting Injectable Antipsychotics: Evidence From Ontario

    Dec 1, 2025, 00:00

  • PCR218 Social Media Listening Analysis of Cannabis Use in Patients With Inflammatory Bowel Disease

    Dec 1, 2025, 00:00

  • EE576 Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment

    Dec 1, 2025, 00:00

  • P44 Early Economic Modeling to Estimate Cost-Effectiveness and Value-Based Price of a Gene Therapy for Urofacial Syndrome

    Dec 1, 2025, 00:00

  • EE459 Exploring the Healthcare Resource Utilization (HCRU) Associated With Chorea in Patients With Huntington's Disease (HD): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • RWD86 From Clinic to Cohort: The VOICE Vitiligo Registry and Bioresource as a Blueprint for High-Fidelity Specialist Registries

    Dec 1, 2025, 00:00

  • P61 Utilizing LLMs to Enhance Patient-Reported Outcome Measures: Application to the EQ-5D and Bolt-ons

    Dec 1, 2025, 00:00

  • HPR12 Accelerating Therapeutic Innovation: Early Results From France’s Accès Direct Scheme

    Dec 1, 2025, 00:00

  • PCR126 Identifying Patient-Reported Outcome Measures to Capture Patients’ Experiences of Symptoms and Impacts of Acute Myeloid Leukemia (AML)

    Dec 1, 2025, 00:00

  • MSR95 Evaluating the Performance of a Supervised Artificial Intelligence Model in Screening Abstracts for Oncology-Focused Targeted Literature Reviews

    Dec 1, 2025, 00:00

  • PCR32 Bimekizumab Improves Work Productivity in Patients With Hidradenitis Suppurativa: 2-Year Results From BE HEARD EXT

    Dec 1, 2025, 00:00

  • MSR165 Performance Evaluation of AI-Assisted Systematic Literature Review for Studies on Burden of HPV-Associated Head and Neck Cancers

    Dec 1, 2025, 00:00

  • HPR231 Unmet Need in IgA Nephropathy (IgAN): Disparity Between Clinical Guidelines and Real-World Practice in Ireland

    Dec 1, 2025, 00:00

  • HTA96 Cost-Effectiveness Assessment of Orphan Drugs in Fran Key Insights from CEESP Reviews (2021-2024)

    Dec 1, 2025, 00:00

  • EE620 Projected Public Health Impact of Synchronized COVID-19 and Influenza Vaccination With a Combination Vaccine in US Older Adults

    Dec 1, 2025, 00:00

  • CO2 A Systematic Literature Review and Meta-Analysis Comparing Robotic-Assisted Mitral Valve Repair Using the Da Vinci Surgical System to Open Mitral Valve Repair

    Dec 1, 2025, 00:00

  • HTA246 Navigating Large Evidence Bases for MTEP Submissions

    Dec 1, 2025, 00:00

  • EPH192 Prevalence of Obesity and Comorbidities Among People With Obesity in China, Japan, and EU5

    Dec 1, 2025, 00:00

  • CO165 Modeling Intelligence Quotient (IQ) Changes Relative to Blood Phe Levels in Individuals With Phenylketonuria (PKU) Treated With Sepiapterin and Sapropterin Dihydrochloride

    Dec 1, 2025, 00:00

  • HPR209 The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways

    Dec 1, 2025, 00:00

  • MSR122 How Far Have We Come With EQ-5D-5L Value Sets? An Updated Systematic Literature Review of 55 Valuation Studies

    Dec 1, 2025, 00:00

  • EE666 Socioeconomic Burden (SOB) of Multiple Sclerosis (MS) in Latin America (LATAM): Trends and Projections 2017-2032

    Dec 1, 2025, 00:00

  • EE155 Cost Analysis of Polatuzumab Vedotin in Combination With Rituximab Cyclophosphamide Doxorubicin and Prednisone in the Treatment of Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma in Portugal

    Dec 1, 2025, 00:00

  • RWD149 Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data

    Dec 1, 2025, 00:00

  • EE630 Quantifying the Opportunity Costs of Intra-Direct Oral Anticoagulants (DOAC) Switching Pathways Across the National Health Service (NHS) in England: A Structured Framework

    Dec 1, 2025, 00:00

  • HPR47 Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and Fran Lessons for Poland

    Dec 1, 2025, 00:00

  • EE407 EIGER: Cost Impact of Progression to Metastatic Disease Amongst US Patients With Gastric and Gastroesophageal Junction Cancer (GCGEJC)

    Dec 1, 2025, 00:00

  • PCR229 The Effects of Disease Modifying Anti-Rheumatic Drugs (DMARDs) on Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analyses

    Dec 1, 2025, 00:00

  • EPH259 Trends and Characteristics of Thrombectomy Use in Acute Ischemic Stroke in Germany (2019-2024): Insights From National Claims Data

    Dec 1, 2025, 00:00

  • RWD63 Development of an LLM-Based Computable Phenotype for Pediatric Lymphoma Subtypes Using Structured and Unstructured Electronic Medical Record Data

    Dec 1, 2025, 00:00

  • HPR201 The French Transitional Coverage Pathway (PECT) for Innovative Therapeutic Medical Devices: A Four-Year Retrospective Analysis

    Dec 1, 2025, 00:00

  • EE481 Global Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HTA200 Individual Therapy or No Therapy at All: Impact of Patient Individual Therapies As ACT in the German AMNOG Process

    Dec 1, 2025, 00:00

  • PCR52 Content Validation of a Modified PozQoL for Assessing HIV Therapies

    Dec 1, 2025, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2025, 00:00

  • EPH108 Exploring the Impact of Patient Characteristics and Reporting Period on Adverse Drug Withdrawal Event Signals in the FAERS Database: A Stratified Disproportionality Analysis Study

    Dec 1, 2025, 00:00

  • HSD26 Comparing Countries’ Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States

    Dec 1, 2025, 00:00

  • CO203 Real-World Effectiveness of Systemic Therapies in Adults with KRAS(G12C) Metastatic Colorectal Cancer in Europe: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • PCR119 Health-Related Quality of Life in Patients With Mild Cognitive Impairment and Dementia and Their Caregivers in Thailand: A Cross-Sectional Study

    Dec 1, 2025, 00:00

  • EQ Health and Wellbeing EQ-HWB: A Psychometric Assessment Across 6 Conditions and the General Population in the United Kingdom

    Dec 1, 2025, 00:00

  • MSR130 Improving Indirect Treatment Comparisons via an Alternative MAIC Patient Weighting Method

    Dec 1, 2025, 00:00

  • EPH95 Evaluation of Safety Signal Management in Europe: Insights From PRAC Reports (2016-2024)

    Dec 1, 2025, 00:00

  • EE738 Treatment With Semaglutide Reduces the Complication Costs Among Type 2 Diabetes Patients With CKD in China: A Short-Term Cost Analysis Based on the FLOW Trial

    Dec 1, 2025, 00:00

  • SA98 Trends in Vaccination at Pharmacies by Race Among Medicaid Recipients: A Claims Analysis

    Dec 1, 2025, 00:00

  • EPH251 The PHEBUS Study: A Retrospective Analysis of the Burden of Pneumococcal Infections in the Pediatric Population Using the French Hospital Discharge Database (PMSI)

    Dec 1, 2025, 00:00

  • HTA92 Cost-Effectiveness Analysis of Aztreonam Avibactam (ATMAVI) ± Metronidazole (MTZ) for the Treatment of Complicated Intra-Abdominal Infections (cIAIs) and Ventilator-Associated Hospital-Acquired Pneumonia (HAP/VAP) Caused by Suspected ...

    Dec 1, 2025, 00:00

  • HTA205 Integrating Health Equity Into Health Technology Assessment: A Scoping Review

    Dec 1, 2025, 00:00

  • PCR15 An Initiative to Improve Patient Organization Engagement at the National Center for Pharmacoeconomics, Ireland

    Dec 1, 2025, 00:00

  • RWD72 Economic Burden of Prostate Cancer Overall and by Stages Based on the French Real-World Nationwide Medico-Administrative Database (SNDS)

    Dec 1, 2025, 00:00

  • SA101 Using a Large Language Model (LLM) for Data Extraction of Studies: Learnings From a Targeted Literature Review (TLR) in Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • EE707 The Economic Value of Self-Administered Subcutaneous Immunoglobulin G (SCIg) in Canada: A Scoping Review

    Dec 1, 2025, 00:00

  • HTA349 Use of AI Methods in NICE Technology Appraisals: What Is the Current Status Quo?

    Dec 1, 2025, 00:00

  • OP18 Overview of Hospital Management of Patients Treated With Thoracic Endovascular Repair (TEVAR) and Revascularization of the Left Subclavian Artery in France Based on the PMSI

    Dec 1, 2025, 00:00

  • CO234 The Association of Glucagon-Like Peptide-1 Receptor Agonists With Hepatopancreatobiliary Diseases in Individuals With Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • RWD101 Improving Data Quality in Oncology Electronic Health Record (EHR)-Derived Databases for Research and Regulatory Decision Making

    Dec 1, 2025, 00:00

  • EE559 Intra-Procedure Cost Variability: A Retrospective Analysis of Real-World Patient Level Information Costing (PLICS) Data for a Minimally Invasive BPO Therapy in the NHS

    Dec 1, 2025, 00:00

  • SA75 Performance of Large Language Model Clinical Data Extraction by Data Domain: A Rapid Systematic Review

    Dec 1, 2025, 00:00

  • EPH55 COVID-19 mRNA-1273 Vaccination in the UK: A Comparative Modeling Study of Alternative Eligibility Criteria

    Dec 1, 2025, 00:00

  • EE289 Costs Associated With the Administration, Postinfusion Monitoring, and Management of Adverse Events (AEs) Related to Novel Drugs for Second-Line (2L+) Treatment of Small-Cell Lung Cancer (SCLC)

    Dec 1, 2025, 00:00

  • CO35 Burden of Illness Among Patients With Transfusion Dependent Beta-Thalassemia in Spain: A Registry-Based Study

    Dec 1, 2025, 00:00

  • PCR115 Health-Related Quality of Life for Patients With Transthyretin Amyloid Cardiomyopathy: A Real-World Study in Europe, Canada, and Japan

    Dec 1, 2025, 00:00

  • EE108 Budget Impact of Introducing Accuchek® Smartguide Real-Time Continuous Glucose Monitoring (RtCGM) Solution for Diabetes Management in Portugal

    Dec 1, 2025, 00:00

  • EE365 Economic Burden of Schizophrenia: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE648 Repeated Breast Surgery After a Lumpectomy in England

    Dec 1, 2025, 00:00

  • HTA186 HTA League of Nations: Which Bodies Were Most Likely to Approve Submissions and for What Disease Areas?

    Dec 1, 2025, 00:00

  • MSR134 Interpreting PRO-CTCAE Data: Defining and Answering the Right Questions

    Dec 1, 2025, 00:00

  • MSR174 Psychometric Evaluation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire Item-10 (Physical Fatigue) and Idiopathic Thrombocytopenic Purpura Bleeding Scale Using LUNA 3 Phase 3 Trial Data

    Dec 1, 2025, 00:00

  • RWD93 Healthcare Resource Utilization Before and After Cardiovascular Disease Diagnosis in the NHS: A Descriptive Cohort Study

    Dec 1, 2025, 00:00

  • HTA294 Role of Technical Engagement in NICE Process Under Proportionate Approach to Technology Appraisals

    Dec 1, 2025, 00:00
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »